S
Scott C. Potter
Researcher at Torrey Pines Institute for Molecular Studies
Publications - 9
Citations - 656
Scott C. Potter is an academic researcher from Torrey Pines Institute for Molecular Studies. The author has contributed to research in topics: Fructose 1,6-bisphosphatase & Prodrug. The author has an hindex of 8, co-authored 9 publications receiving 613 citations. Previous affiliations of Scott C. Potter include Harvard University.
Papers
More filters
Journal ArticleDOI
MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes
Mark D. Erion,Paul D. van Poelje,Qun Dang,Srinivas Rao Kasibhatla,Scott C. Potter,M. Rami Reddy,K. Raja Reddy,Tao Jiang,William N. Lipscomb +8 more
TL;DR: The findings suggest that potent and specific FBPase inhibitors represent a drug class with potential to treat type 2 diabetes through inhibition of GNG.
Journal ArticleDOI
Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.
Qun Dang,Yan Liu,Daniel K. Cashion,Srinivas Rao Kasibhatla,Tao Jiang,Frank Taplin,Jason D. Jacintho,Haiqing Li,Zhili Sun,Yi Fan,Jay DaRe,Feng Tian,Wenyu Li,Tony Gibson,Lemus Robert Huerta,Paul D. van Poelje,Scott C. Potter,Mark D. Erion +17 more
TL;DR: Extensive lead optimization of both the thiazole FBPase inhibitors and their prodrugs culminated in the discovery of compound 35n (MB06322) as the first oralFBPase inhibitor advancing to human clinical trials as a potential treatment for T2DM.
Journal ArticleDOI
Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes.
Qun Dang,Srinivas Rao Kasibhatla,K. Raja Reddy,Tao Jiang,M. Rami Reddy,Scott C. Potter,James M. Fujitaki,Paul D van Poelje,Jingwei Huang,William N. Lipscomb,Mark D. Erion +10 more
TL;DR: A series of orally bioavailable FBPase inhibitors identified following the combined discoveries of a low molecular weight inhibitor series with increased potency and a phosphonate prodrug class suitable for their oral delivery are reported.
Journal ArticleDOI
Inhibition of Fructose 1,6-Bisphosphatase Reduces Excessive Endogenous Glucose Production and Attenuates Hyperglycemia in Zucker Diabetic Fatty Rats
Paul D. van Poelje,Scott C. Potter,Visvanathan Chandramouli,Bernard R. Landau,Qun Dang,Mark D. Erion +5 more
TL;DR: The studies confirm that excessive gluconeogenesis plays an integral role in the pathophysiology of type 2 diabetes and suggest that FBPase inhibitors may provide a future treatment option.
Journal ArticleDOI
Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics.
Qun Dang,Srinivras Rao Kasibhatla,Wei Xiao,Yan Liu,Jay DaRe,Frank Taplin,K. Raja Reddy,Gerard R. Scarlato,Tony Gibson,Paul D. van Poelje,Scott C. Potter,Mark D. Erion +11 more
TL;DR: Intravenous administration ofhibitor 4.4 to Zucker diabetic fatty rats led to rapid and robust glucose lowering, thereby providing the first evidence that FBPase inhibitors could improve glycemia in animal models of type 2 diabetes.